Xenetic Biosciences, Inc. (XBIO)

Advancing Innovative Immune-Oncology Technologies

We are a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications.

More About Us

Targeting Neutrophil Extracellular Traps (NETs)

NETs are a driver of cancer progression and metastasis and can also contribute to resistance to chemotherapy, checkpoint inhibitors and radiotherapy.

DNase I Oncology Platform

Oncology platform aimed at improving cancer therapies with the opportunity to address multiple oncology indications, including pancreatic cancer and other solid tumors.

Pipeline

Latest News

Oct 22, 2024

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 17, 2024

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Investor Presentation

View Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates